TechnoPhage announced the spin-off of T-Oncology AG, which will focus on the development of Antibody Drug Conjugates (ADCs), based on the...
The continued growth of Technophage from a small biotech into a clinical-stage biopharma has resulted in the company making the Financial Times'...
Technophage is proud to announce that it has recently been granted with the ‘COTEC Innovative Status 2022’. COTEC Portugal is the main Portuguese...
Invest in our products
Learn more about GMP manufacturing
Who we are, What we do
TechnoPhage is committed to the development of biological and chemical products for infection, neurosciences and ophthalmology